PPIDT00253
Drug Information
| Name | Nivolumab |
|---|---|
| Sequence | QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK |
| DrugBank_ID | DB09035 |
| Type | biotech |
| Indication | Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, hepatocellular carcinoma, and esophageal cancer.[L12129, L42970] The indication for classical Hodgkin lymphoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, and hepatocellular carcinoma were approved under accelerated approval based on the overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.[L12129] Nivolumab is also approved for the treatment of HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma when used in combination with a fluoropyrimidine- and platinum-containing chemotherapy regimen.[L39040] In combination with [relatlimab], nivolumab is indicated for the treatment of patients ≥12 years old with unresectable or metastatic melanoma.[L41265,L49996,L50001] In combination with [cisplatin] and [gemcitabine], nivolumab is indicated as a first-line treatment in adult patients with unresectable or metastatic urothelial carcinoma.[L12129] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intravenous |
10 MG/ML
|
| Injection | Intravenous |
10 mg/ml
|
| Injection | Intravenous |
10 mg/1mL
|
| Injection, solution, concentrate | Intravenous; Parenteral |
10 MG/ML
|
| Solution | Intravenous |
10 mg / mL
|
| Solution | Intravenous |
100.000 mg
|
| Solution | Intravenous |
100 mg/10ml
|
| Injection, solution | Intravenous |
10 mg/ml
|
| Solution | Intravenous |
40 mg/4ml
|
| Solution | Intravenous drip |
10 mg/mL
|
| Solution | Intravenous |
4000000 mg
|
| Solution | Intravenous |
10000000 mg
|
| Injection | Intravenous |
|
| Injection, solution, concentrate | Intravenous |
|
| Solution | Intravenous |
|
| Injection, solution, concentrate | Intravenous |
10 mg/1ml
|